You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration

    SBC: EscaZyme Biochemicals, LLC            Topic: N

    Project Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostl ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity

    SBC: Colorado Research Partners LLC            Topic: 300

    Our goal is to develop a firstin class therapeutic agent that directly blocks the metabolism of fructosea key component in sugarIntake of sugarsucroseand high fructose corn syrupHFCSinduces metabolic syndrome and diabetes in laboratory animals and are strongly associated with obesity and diabetes in humansBoth sucrose and HFCS contain fructosewhich stimulates food intake by inducing leptin resista ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Evidence-Based Pain Intervention for Veterans: Leveraging Mobile and Social Media

    SBC: Pro-Change Behavior Systems Inc            Topic: NCCIH

    Chronic musculoskeletal pain creates a significant public health burden, and Veterans are disproportionately affected. The frequency and extent of co-occurrence of pain and PTSD, pain and Traumatic Brain Injury (TBI), all three conditions (Post-deployment Multi-symptom Disorder (PMD), and other multi-symptom syndromes can complicate and reduce the effectiveness of pain treatment. Furthermore, the ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II

    SBC: MBC Pharma, Inc.            Topic: NCI

    Project Summary AbstractThe overall aim of this project is to further develop a novel gemcitabine ibandronate conjugate alone and or as part of a combination therapy for the treatment of osteosarcoma and associated metastasesThe conjugate consists of chemically linked anticancer antimetabolite Gemcitabine and the bone homing bisphosphonate IbandronateThe novel conjugate directly addresses the limi ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Stable Glucagon for Treatment of Hyperinsulinism

    SBC: AMIDEBIO, LLC            Topic: 200

    SUMMARY ABSTRACT A series of glucagon analogues will be designedproduced at milligram levelstested for solution stability and both in vitro and in vivo activity with the goal of providing a long term treatment for hyperinsulinism

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease

    SBC: EPIVAX, INC.            Topic: 200

    ABSTRACT SignificanceGravesdiseaseGDone of the most prevalent autoimmune diseasesis caused by stimulating autoantibodiesTSAbto the Thyroid Stimulating Hormone ReceptorTSHRresulting in hyperthyroidismCurrent methods for managing hyperthyroidism in GD target excess thyroid hormone secretion by ablation or removal of the thyroid or by blocking thyroid hormone synthesisEach of these therapies is assoc ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Non invasive risk assessment tool for pediatric heart failure

    SBC: CORAMIR BIOMEDICAL, INC.            Topic: NHLBI

    ABSTRACT Heart Failure HF in pediatric patients is a devastating disease that is difficult to evaluate even with invasive hospital procedures Importantly and unique to the pediatric population approximately of pediatric HF patients spontaneously recover normal heart function within year of diagnosis Unfortunately there is no reliable clinical parameter or biomarker that allows pedia ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Bone Targeted Antibiotics

    SBC: MBC Pharma, Inc.            Topic: R

    Project Summary AbstractThe overall goal of this project is to develop novel bone targeted conjugates of clinically relevant antibiotics for the treatment of osteomyelitisThese compounds are new chemical entities built from known and approved antibiotics and bisphosphonateswhich are connected via biodegradable phosphate linkerThe design of these drugs exploits the high bone affinity of bisphosphon ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Antimicrobial Peptides to Target Gram negative Pathogens

    SBC: Aurora Oncology, Inc.            Topic: NIAID

    The dramatic and ever increasing emergence of medically relevant strains of bacteria resistant to traditional antibiotics is now a major human health issue Antibiotic resistance has arisen due to the extensive clinical use of classical antibiotics We have now seen the development of so called Superbugs that are resistant to most or all of the available antibiotics The Infectious Diseases Soci ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Topical proprietary biologic to treat oral mucositis

    SBC: Allander Biotechnologies            Topic: NIDCR

    Summary Oral mucositisa severe oral ulcerationis a common toxic effect of radioor chemoradio therapy and a limiting factor to using the maximum dose of radiation for effective cancer treatmentAt leastand up toof cancer patients treated with standard chemotherapy regimens or upper body radiation develop oral mucositisIntensity modulated RTIMRTlessens chronic side effectsbut not the acute toxicity s ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government